Paul Langlie Martin, MD, PhD
For most of my career in Pediatric Hematology/Oncology I have focused on the use of stem cell transplant for the treatment of pediatric leukemias (ALL, AML, CML and JMML) and other non-malignant blood disorders, such as thalassemia, hemaphagocytic disorders, Wiskott-Aldrich, aplastic anemia, Diamond-Blackfan Anemia, as well as inherited metabolic diseases. In addition to focusing on determining the best use of stem cell transplants for these disorders, I have also been involved in clinical research investigating the prevention and treatment of transplant related morbidity, particularly veno-occlusive disease of the liver, infections and diffuse alveolar hemorrhage. As study chair for the Children's Oncology Group protocol 9904, I was involved in the development, implementation and analysis of a large, international frontline study of childhood acute lymphoblastic leukemia. Results from this study show that a significant number of children with certain favorable cytogenetic abnormalities in their leukemic cells and who have a rapid response to their initial chemotherapy can expect to have a >95% chance of cure when treated with relatively low intensity chemotherapy.
For most of my time at Duke I have concentrated on providing high quality care for high risk leukemia patients who require high intensity therapies, such as stem cell transplant and immunotherapy. As a member of the Pediatric Transplant and Cellular Therapy Division I provide clinical care for these patients. As a member of various cooperative groups and local PI for several drug trials, I have worked to provide better care and more specific therapies for the toxicities associated with stem cell transplant.
I have also collaborated with the Pediatric Immunology Division to provide a life-saving therapy for a small group of patients with thymic dysfunction, which causes severe immunodeficiency. Our clinical team now provides support during these patients hospital admissions for donor thymus tissue implantation.
Education and Training
- Fellow, Pediatric Hematology/Oncology, Pediatrics, Yale University, 1989 - 1992
- Resident, Pediatrics, Yale University, 1988 - 1989
- Intern, Pediatrics, Yale University, 1987 - 1988
- Ph.D., Washington University in St. Louis, 1987
- M.D., Washington University in St. Louis, 1987
Selected Grants and Awards
- A Phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in pediatric patients with relapsed and refractory B-cell acute lymphoblastic leukemia
- PHASE 3 STUDY EVALUATING GENE THERAPY BY TRANSPLANTATION OF AUTOLOGOUS CD34+ STEM CELLS TRANSDUCED EX VIVO WITH THE LENTIGLOBIN BB305 LENTIVIRAL VECTOR IN SUBJECTS WITH SEVERE SICKLE CELL DISEASE
- A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant
- Transfusion Medicine and Hematology
- PBMTC SUP 1601 Pathogen Identification in Pediatric HSCT
- A Phase 2 Multicenter Single arm Study of Moxetumomab Pasudotox in Pediatric Subjects with Relapsed or Refractory pALL
- Pediatric Oncology Group (POG)